Indoco Remedies has informed that the Board of Directors of the Company at its Meeting held today 19th October, 2023 has considered and approved the following, Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30th September, 2023 along with the Limited Review Report with unmodified opinion on the aforesaid Unaudited Financial Results, Issuance of a Corporate Guarantee of Rs. 17,00,00,000 in favour of Citibank N.A. in respect of the working capital facilities to be availed by Florida Pharmaceutical Products LLC, step down subsidiary of the Company. The details as required under SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated 13th July 2023 are attached as ‘Annexure A’. It enclosed copies of the following: Unaudited Standalone and Consolidated Financial Results as per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; Limited Review Report with unmodified opinion issued by Statutory Auditors Gokhale & Sathe, Chartered Accountants.
The above information is a part of company’s filings submitted to BSE.